Tagged with P

Orient Europharma Co. You founded Orient Europharma in 1982, nearly 30 years ago. As you approach the 30 year mark, how has the company evolved to the way it is today, and how would you describe the company to our readers? I left Upjohn in 1982 and established Orient Europharma (OEP) as a…

Pfizer Serbia Pfizer is increasingly interested in emerging markets, with a focus very much on Latin America and Asia. Given this, why is Serbia exciting for Pfizer today? Serbia is interesting for most multinational companies, firstly because of the county’s geographic location, and secondly because of the relatively high population for the…

Hospira Taiwan What is exciting about the Taiwanese market for Hospira today? Hospira is a US-based company, which used to be part of Abbott Laboratories. A major part of the portfolio for the company is devices, which is mainly driven by its Medication Management Systems (MMS) portfolio. The rest of the company’s…

Association of Producers of generic medicines in Romania (APMGR) APMGR is obviously a rather young association that has only really been active since about a year now. Can you first comment on the timing that the Association was called into life? The timing has been quite good, as the generics industry is currently experiencing a strong momentum. Every country,…

Standard Chem & Pharm I was very surprised to see a company called ‘Standard Chemical and Pharmaceutical’ ranked amongst the top three local players in Taiwan: it seems as though your company is far from standard. What is it about Standard Pharm that stops it from being just an average pharmaceutical company? My father,…

Martindale Pharma Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When I was invited to join Martindale I was tasked with the mission to identify a strategy for the company and…

Eisai Europe As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary Hendler (GH): Eisai are currently present in 17 European markets as Eisai and several others via distributors. However it is…

Watson Pharmaceuticals UK Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since its creation in 1984, Watson was a generic pharmaceutical company that was predominantly US based until the acquisition of Arrow…

Giddi Pharma Co. Ltd. Giddi Pharma was founded in 1995. What was the vision behind the creation of the company? What founding principles did you have when you founded Giddi? When I founded this company, biotech was an industry that was displaying high potential. When looking at how to get involve d in the…

Bayer Schering Pharma The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global market. Given that the company seems to be finished with mergers and acquisitions for the time being, what are Bayer…

Productos Roche S.A. What has been the evolution of Roche’s operations in Colombia’s over the course of its proud 52-year history here? As with almost all pharmaceutical companies with commercial operations in Latin America, we began our business here in Colombia with a production plant. The plant has closed since 1997 as our…

Astellas Poland You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother companies Yamanouchi and Fujisawa. Could you describe to our readers the evolution of the affiliate since the merger? Astellas has…